Gene therapy for renal injury model rat using an adenovirus vector encoding the soluble rat Crry gene

Clinical and Experimental Nephrology

Volumn 6, Issue 4, 2002, Pages 216-223

  Sogabe, Hajime ^a   Quigg, Richard J ^b   Okada, Noriko ^c   Miyata, Toshio ^d   Inagi, Reiko ^d   Kurokawa, Kiyoshi ^d   Fujita, Toshiro ^e   Nangaku, Masaomi ^e  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

^c NAGOYA CITY UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Complement; Complement regulatory protein; Glomerulonephritis

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; MESSENGER RNA; RECOMBINANT COMPLEMENT REGULATORY PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYY GENE; GENE; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOREGULATION; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE;

EID: 0036964604     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101570200037     Document Type: Article

References (50)

1. Couser WG. The pathogenesis of glomerulonephritis. Kidney Int 1993;42:S19-26.
2. Couser WG, Nangaku M, Shankland SJ, Johnson RJ. Molecular mechanisms of experimental glomerulonephritis: an overview. Nephrology 1997;3:S633-7.
3. Volanakis JE, Frank M. The Human complement system in health and disease. New York: Dekker, 1993.
4. Lambris JD. The third component of complement: chemistry and biology. Berlin: Springer, 1990.
5. Noris M, Ruggenenti P, Perna A, Orisio S, Caprioli J, Skerka C, et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999;10:281-93.
6. Ying L, Schlesinger M, Carmi R, Shalev H, Haider N, Beck G, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Human Genetics 1999;65:1538-46.
7. Yamada K, Hori Y, Hanafusa N, Okuda T, Nagano N, Miura NH, et al. Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Int 2001;59:137-46.
8. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers M, Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 1993;151:4295-305.
9. Matsuo S, Ichida S, Takizawa H, Okada N, Baranyi L, Iguchi A, et al. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med 1994;180:1619-27.
10. Hatanaka Y, Yuzawa Y, Nishikawa K, Fukatsu A, Okada N, Okada H, et al. Role of a rat membrane inhibitor of complement in anti-basement membrane antibody-induced renal injury. Kidney Int 1995;48:1728-37.
11. Nomura A, Nishikawa K, Yuzawa Y, Okada H, Okada N, Morgan BP, et al. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J Clin Invest 1995;96:2348-56.
12. Nishikage H, Baranyi L, Okada H, Okada N, Isobe K, Nomura A, et al. The role of a complement regulatory protein in rat mesangial glomerulonephritis. J Am Soc Nephrol 1995;6:234-42.
13. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, et al. Transgenic mice overexpressing the complement inhibitor Crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med 1998;188:1321-31.
14. Alexander JJ, Lim A, He C, MacDonald RL, Holers VM, Quigg RJ. Renal, central nervous system and pancreatic overexpression of recombinant soluble Crry in transgenic mice: a novel means of protection from complement-mediated injury. Immunopharmacology 1999;42:245-54.
15. Schiller B, Cunningham PN, Alexander JJ, Bao L, Holers VM, Quigg RJ. Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure. J Am Soc Nephrol 2001;12:71-9.
16. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr., Carson GR, Concino MF, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-51.
17. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-32.
18. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997;389:239-42.
19. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7:33-40.
20. Svensson EC, Black HB, During DL, Tripathy SK, Goldwasser E, Hao Z, et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of replication-defective adenoviral vector. Hum Gene Ther 1997;8:1797-906.
21. He X, Goldsmith CM, Marmary Y, Wellner RB, Parlow AF, Nieman LK, et al. Systemic action of human growth hormone following adenovirus-mediated gene transfer to rat submandibular glands. Gene Ther 1998;5:537-41.
22. Marmary Y, Parlow AF, Goldsmith CM, He X, Wellner RB, Satomura K, et al. Construction and in vivo efficacy of a replication-deficient recombinant adenovirus encoding murine growth hormone. Endocrinology 1999;140:260-5.
23. Sauter BV, Martinet O, Zhang W-J. Mandeli J, Woo SLC. Adenovirus mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 2000;97:4802-7.
24. Quigg RJ, Lo CF, Alexander JJ, Sneed AE III, Moxley G. Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA. Immunogenetics 1995;742:362-7.
25. Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem 1991;266:19867-70.
26. Kozak M. The scanning model for translation: an update. J Cell Biol 1989;108:229-41.
27. Nangaku M, Meek RL, Pippin J, Gordon KL, Morgan BP, Johnson RJ, et al. Transfected CD59 protects mesangial cells from injury induced by antibody and complement. Kidney Int 1996;50:257-66.
28. Takizawa H, Okada N, Okada H. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J Immunol 1994;152:3022-8.
29. Peeters MJ, Patijn GA, Lieber A, Meuse L, Kay MA. Adenovirusmediated hepatic gene transfer in mice: comparison of intravascular and biliary administration. Hum Gene Ther 1996;7:1693-9.
30. Morita Y, Nomura A, Yuzawa Y, Nishikawa K, Hotta N, Shimizu F, et al. The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1997;8:1363-72.
31. Nomura A, Morita Y, Maruyama S, Hotta N, Nadai M, Wang, et al. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol 1997;151:539-47.
32. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999;10:2323-31.
33. Nangaku M, Pippin J, Couser WG. C6 mediates chronic progression of tubulointerstitial damage in remnant kidney rats. J Am Soc Nephrol (in press).
34. Hori Y, Yamada K, Hanafusa N, Okuda T, Okada N, Miyata T, et al. Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria. Kidney Int 1999;56:2096-106.
35. Nangaku M. Complement regulatory proteins in glomerular diseases. Kidney Int 1998;54:1419-28.
36. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor I on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995;5:1888-94.
37. Yu J, Abagyan R, Dong S, Gilbert A, Nussenzweig V, Tomlinson S. Mapping the active site of CD59. J Exp Med 1997;185:745-53.
38. Krych M, Clemenza L, Howdeshell D, Hauhart R, Hourcade D, Atkinson JP. Analvsis of the functional domeins of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem 1994;269:13273-8.
39. Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK, Yeh CG. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. J Immunol 1997;158:2872-81.
40. Zhang H, Yu J, Bajwa E, Morrison SL, Tomlinson S. Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest 1999;103:55-61.
41. x-Glycosylated complement inhibitory protein. Science 1999;285:595-9.
42. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, et al. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996;50:148-55.
43. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beat or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993;92:2597-601.
44. Tsujie M, Isaka Y, Ando Y, Akagi Y, Kaneda Y, Ueda N, et al. Gene transfer targeting interstitial fibroblasts by the artificial viral envelope-type hemagglutinating virus of Japan liposome method. Kidney Int 2000;57:1973-80.
45. Zhu G, Nicolson AG, Coeley BD, Rosen S, Sukhatme VP. In vivo adenovirus-mediated gene transfer into normal and cystic rat kidneys. Gene Ther 1996;3:298-304.
46. Zhu G, Nicolson AG, Zheng XX, Strom TB, Sukhatme VP. Adenovirus-mediated beta-galactosidase gene delivery to the liver leads to protein deposition in kidney glomeruli. Kidney Int 1997;52:992-9.
47. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, et al. Gene therapy by skeltal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996;2:418-23.
48. Osada S, Ebihara I, Setoguchi Y, Takahashi H, Tomino Y, Koide H. Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene. Kidney Int 1999;55:1234-40.
49. Ueki K, Yamauchi T, Tamemoto H, Tobe K, Yamamoto-Honda R, Kaburagi Y, et al. Restored insulin-sensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy. J Clin Invest 2000;105:1437-45.
50. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig. a soluble murine complement inhibitor. J Immunol 1998;160:4553-60.